Lv51
874 积分 2023-07-26 加入
放疗联合靶向、免疫治疗和化疗治疗不可手术切除的肝内胆管癌的疗效及安全性研究
5小时前
已完结
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
3天前
已完结
Immunotherapies for hepatocellular carcinoma
6天前
已关闭
Immunotherapies for hepatocellular carcinoma
6天前
已关闭
Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
13天前
已关闭
Impact of immune‐related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
13天前
已完结
进展期胃癌新辅助化疗前后IL-6、IL-10的变化及其临床意义
14天前
已关闭
Gastric cancer
15天前
已完结
皖公网安备34019202002308
